Compare Novo Nordisk A/S (NVO) vs New York Times Co (NYT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Novo Nordisk A/S vs New York Times Co — how do they compare? Novo Nordisk A/S trades at $46.32 (market cap $207.85B), while New York Times Co trades at $63.73 (market cap $10.28B). The key difference: Novo Nordisk A/S is far larger — about 20.2× New York Times Co's market cap, and Novo Nordisk A/S pays the higher dividend (3.81%). Which is the better fit depends on your goals.
| NVO | NYT | |
|---|---|---|
Market Cap | $207.85B | $10.28B |
Sector | Health | Media |
52-Week High | $63.98 | $85.86 |
52-Week Low | $35.29 | $54.66 |
Enterprise Value | $222.55B | $9.67B |
Dividend Yield | 3.81% | 1.44% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Novo Nordisk (NVO) trades at $46.465, down 2.65% today, with a neutral technical signal. The stock shows strong fundamentals, including a P/E of 11.62, net income margin of 35.35%, and consistent earnings beats in recent quarters. Recent news highlights competitive pressures from Eli Lilly and mixed investor reactions to Q2 2026 results, despite an upwardly revised full-year outlook.
Outlook remains positive due to robust GLP-1 drug demand and profitability, but risks include pricing pressure and competition. Analysts are predominantly bullish (57.9% buy ratings), supporting a favorable long-term view despite near-term volatility.
The New York Times (NYT) trades at $63.93, down 1.34% amid bearish technical signals despite strong Q2 2026 earnings beats. Revenue growth continues with 2025 revenue reaching $2.82B and net income margin expanding to 12.17%. The stock faces technical pressure with RSI at oversold levels near key support at $62-63, while analyst consensus remains cautious with 65% hold ratings.
NYT demonstrates solid fundamental growth with expanding profitability and digital subscription strength, but faces near-term headwinds from slowing subscriber growth and technical weakness. The $77.50 consensus price target suggests 21% upside potential, though execution risks and competitive pressures warrant monitoring for current investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Novo Nordisk A/S
With almost 50% market share by volume of the global insulin market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments, and oral antidiabetic agents. Novo also has a biopharmaceutical segment (constituting roughly 15% of revenue) that specializes in protein therapies for hemophilia and other disorders.
Read more on NVO →About New York Times Co
New York Times Co is an American media company known for publishing its flagship newspaper, The New York Times. The company also operates the International New York Times newspaper, as well as digital properties such as nytimes and various smartphone applications. Circulation of The New York Times is the source of revenue for the company, followed by print and digital advertising and its paid digital-only subscription to The New York Times. The company has a daily print circulation of over 500,000 and 1,000,000 on Sundays. The source of growth for The New York Times is its digital subscription service, which has over 1,000,000 paid users.
Read more on NYT →
